Background: Accurate assessment of neoadjuvant chemotherapy (NAC) response with positron emission tomography/ computed tomography (PET/CT) or magnetic resonance imaging (MRI) may provide appropriate operation guidelines for individual breast cancer patients. Purpose: To compare the values of PET/CT and MRI for response evaluation following NAC in breast cancer patients. Material and Methods: Thirty-three consecutive patients who underwent NAC were included. PET/CT and MRI were performed before and one to four weeks after NAC. With response evaluation of PET/CT and MRI, patients with complete/partial responses on imaging studies were considered to be responders, and those showing stable/progressive disease non-responders. Peak standardized uptake value corrected for lean body mass (SULpeak) and metabolic tumor volume (MTV) were measured from PET/CT, and unidimensional diameter (1D) and tumor volume (TV) from MRI. Reduction rates for each parameter were calculated (Á%SULpeak, Á%MTV, Á%1D, and Á%TV). The pathological response for NAC as reference was evaluated after surgical resection of the remaining tumor in the breast. Results: We identified 17 pathological responders and 16 non-responders. PET/CT had lower specificity and accuracy, but higher sensitivity than MRI, although no significant difference was found between PET/CT and MRI. Following NAC, there were significant differences between pathological responders and non-responders in SULpeak (P < 0.001), MTV (P < 0.001), 1D (P ¼ 0.0003), TV (P ¼ 0.038), Á%SULpeak (P ¼ 0.001), Á%MTV (P < 0.001), Á%1D (P < 0.001), and Á%TV (P ¼ 0.001). Conclusion: PET/CT showed lower specificity and accuracy than MRI in evaluating responses to NAC, but both PET/CT and MRI parameters may have predictive value in distinguishing therapeutic responders and non-responders following NAC.
Introduction
Preoperative neoadjuvant chemotherapy (NAC) has been used increasingly to downstage breast cancer and reduce or eliminate micrometastatic disease (1) . It has been noted that early assessment of the response to NAC could allow for more adequate treatment monitoring, surgical planning, and for predictions of treatment outcome (2, 3) .
Currently, imaging studies such as mammography, ultrasonography, magnetic resonance imaging (MRI), and positron emission tomography/computed tomography (PET/CT) are performed to evaluate responses to NAC in breast cancer patients. MRI has been used widely for the diagnosis and evaluation of therapeutic response, and several studies have reported that MRI before and after NAC provide reliable information for predicting NAC responses (4) (5) (6) .
For tumor response evaluation in anatomical imaging studies, widely applied criteria include the World Health Organization (WHO) criteria, response evaluation criteria in solid tumors (RECIST) version 1.0 and revised RECIST version 1.1 (7) (8) (9) . However, these criteria have limited accuracy due to delay between treatment and tumor shrinkage, requirement of several treatment cycles, and arbitrary cutoff values of 30% or 50% reduction, which were not based on outcome studies. Conversely, it has been noted that response evaluation by measurements on MRI is reliably accurate and can provide important prognostic information regarding treatment outcome (10) (11) (12) . Several reports showed that response evaluation after NAC might be surrogate for the prediction of prognosis (13, 14) .
PET/CT is expected to be a more accurate technique for NAC response because it is superior to current imaging studies for distinguishing tumor tissue from necrotic or fibrotic tissue. For tumor response evaluation with PET/CT, the European Organization for Research and Treatment of Cancer (EORTC) guidelines were recommended since introduced in 1999 (15) . In 2009, Wahl et al. (16) proposed newer guidelines, the positron emission tomography response criteria in solid tumors (PERCIST). Many studies have demonstrated that PET and PET/CT are useful for monitoring treatment response in breast cancer patients during or after NAC (17) (18) (19) (20) (21) . There are several studies comparing PET/CT and MRI in the prediction of NAC response, including our preliminary results presented at the SNM Annual Meeting in 2010 (21) (22) (23) . However, whether volumetric measurement is more accurate than unidimensional measurements for response evaluations of NAC remains controversial for both PET/CT and MRI.
The purpose of this study was to compare the diagnostic performance of PET/CT and MRI for the evaluation of NAC response and to analyze volume parameters using both PET/CT and MRI for the prediction of responses.
Material and Methods

Patients
Thirty-three consecutive patients with newly diagnosed non-inflammatory, breast cancer that underwent anthracycline-and taxane-based NAC were reviewed retrospectively. For all patients, both PET/CT and dynamic contrast-enhanced MRI were performed before and one to four weeks after NAC. The time interval from PET/CT scan to MRI was zero to seven days. Either breast-conserving surgery or modified radical mastectomy was performed less than one month after completion of NAC. Histopathological examinations were used to make the final diagnosis after surgery. The most common histologic subtype was invasive ductal carcinoma. Stage IIB breast cancer was most common, followed by stages IIIA, IIA, and IIIB. Patients and tumor characteristics are shown in Table 1 .
The institutional review board approved the study protocol. The need for written informed consent was waived. 
PET/CT imaging acquisition and analysis
The methodology of PET/CT scanner details and acquisition parameters are described in the supplementary material. Two experienced nuclear medicine physicians reviewed PET/CT at baseline and after NAC, blinded of the pathology results. Intensities of 18F-FDG uptake were quantified by calculating standardized uptake values corrected for lean body mass in a 1-cm 3 spherical volume of interest (VOI) from the hottest voxel (SULpeak) and metabolic tumor volume (MTV) using a fixed threshold of 2.5 and the Mirada XD3 software (Mirada Medical, Oxford, UK). The primary tumor was delineated manually in the baseline PET/CT, and the same VOI was placed for the PET/ CT after NAC. In concerning inter-observer variability associated manual delineation, an autosegmentation was implemented. The percentage changes in SULpeak and MTV between the two PET/CT scans were calculated as follows:
MRI acquisition and analysis
Scanner details and acquisition parameters of MRI are described in the supplementary material. Two dedicated radiologists experienced in evaluating MRI of the breast performed both the unidimensional (1D) and volumetric measurements using segmentation analysis and tracking (SAT) tools on a TeraRecon AquarisWorkstation (San Mateo, CA, USA). We used post-processing subtraction axial images on the early phase of measurements (24, 25) . This dedicated software automatically segmented an enhanced tumor by region, growing internally with a single click. If necessary, the outlines of the segmented target lesions were modified by the radiologists for a more accurate volumetric analysis using SAT. A tumor volume calculation was based on a voxel-wise approach by summing of boxes meeting the enhancement criteria. The 1D and volume of an enhanced tumor (TV) were reported automatically by this software. According to RECIST 1.1 (9), tumors >1 cm, and nodes with a short axis >1.5 cm in length, were considered measurable and assessed as target lesions. The 1D of a maximum of two target lesions was assessed. After chemotherapy, if these target lesions were too small to measure, it was assigned a default value of 5 mm, and if they disappeared completely it was recorded as 0 mm. If a tumor fragmented into multiple smaller masses, the diameters of all fragmented portions were added to the sum. TV was calculated by means of the dynamic MRI study, summing the contrast-enhanced region in each image multiplied by the slice thickness. The percentage changes in 1D and TV between the two MRI scans were calculated as follows:
Response assessment PET/CT response was assessed by PERCIST 1.0 (16): complete metabolic response (CMR), partial metabolic response (PMR), stable metabolic disease (SMD), and progressive metabolic disease (PMD). Response to NAC assessed by MRI was categorized according to RECIST 1.1 (9): complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD).
Patients with CMR/PMR on PET/CT and CR/PR on MRI were considered to be responders, and SMD/ PMD on PET/CT and SD/PD on MRI to be nonresponders. The pathological response for NAC was evaluated after surgical resection of the remaining tumor in the breast according to Sataloff et al. (26) . The pathological response was defined by tumor necrosis or fibrosis of more than 50% on pathology and nonresponse by necrosis or fibrosis of less than 50%, regardless of the presence of in situ or invasive carcinomas. The complete pathological response was defined as the absence of invasive or in situ carcinomas in the breast.
Statistical analysis
Statistical analyses were carried out using software (SPSS, version 13.0; SPSS, Chicago, IL, USA). Differences between pathological responders and nonresponders were analyzed using nonparametric MannWhitney U test. ROC analysis was performed to determine the best cut-off value for discriminating pathological responders. The area under the curve (AUC) was measured and sensitivity, specificity, accuracy, positive predictive value (PPV), and negative predictive value (NPV) of PET/CT and MRI parameters are reported. All quantitative values are expressed as means AE SDs. All tests are two-sided, and P values < 0.05 were considered to indicate statistical significance.
Results
Correlation with pathological response
Based on the pathology results after surgery, there were 17 pathological responders (52%) and 16 non-responders (48%). Among the pathological responders, three showed complete responses. Individually, the pathological response was observed in 75% ( individuals were defined as responders according to PET/CT, but non-responders according to MRI. Of these ten patients, seven were pathological non-responders and three were pathological responders after surgery (Fig. 1 ). Five patients with pathological nonresponses were judged as being responders according to both PET/CT and MRI (Fig. 2) . The sensitivity, specificity, accuracy, PPV, and NPV of the pathological response with PET/CT and MRI were 100%, 25%, 63.6%, 58.6%, and 100%, and 88.2%, 62.5%, 75.7%, 71.4%, and 83.3%, respectively (Table 2) . Although PET/CT had lower specificity, accuracy, and PPV, but higher sensitivity and NPV than MRI, there was no statistically significant difference between the performances of PET/CT and MRI. Table 3 shows the mean values of SULpeak, MTV, 1D, TV before and after NAC, and % changes in pathological responders and non-responders. Following NAC, there were significant differences between pathologic responders and non-responders in SULpeak (0. 
Prediction of NAC responses
ROC curves of Á%SULpeak, Á%MTV, Á%1D, and Á%TV were plotted to assess predictions of pathological response, whereas other parameters for PET/ CT and MRI were not suitable (Fig. 3) . The AUCs for Á%SULpeak, Á%MTV, Á%1D, and Á%TV were 0.867, 0.833, 0.812, and 0.811, respectively (P ¼ 0.001, 0.002, 0.004, and 0.005, respectively; 95% CI ¼ 0.735-0.998, 0.677-0.990, 0659-0.965, and 0.644-0.975, respectively). The AUCs among these variables were not significantly different.
As indicated in Table 4 , the Á%SULpeak with a cutoff value of 70% demonstrated sensitivity of 70.5%, specificity of 93.7%, and accuracy of 81.8%, while Á%MTV with a cutoff value of 96% demonstrated sensitivity of 70.6%, specificity of 87.5%, and accuracy of 78.8%. For MRI, with a cutoff value of 51.9% for Á%1D, the sensitivity, specificity, and accuracy values were 52.9%, 93.7%, and 72.7%. With a cutoff value of 60.9% for Á%TV, the values were 88.2%, 62.5%, and 75.7%.
Discussion
The present study demonstrated that PET/CT and MRI parameters following NAC and % changes between baseline and after NAC have good predictive value for NAC response in breast cancer patients. Among PET/CT parameters, SULpeak and MTV after NAC, Á%SULpeak, and Á%MTV showed significant difference between pathologic responders and non-responders, while those parameters of baseline PET/CT were not correlated with pathologic response. These results are similar to those of other studies in which SUVmax after NAC and decrease in SUVmax after NAC was significantly different between pathologic responders and non-responders (17, 27) .
Volumetric analysis in PET/CT is challenging because it represents the total metabolically active tumor cells and their heterogeneous uptake pattern (28) . For other malignancies, there have been studies demonstrating that measurement of volume by PET/ CT is useful in the assessment of treatment (28-31). Roedl et al. (29) evaluated 51 esophageal cancer patients who underwent PET/CT before and after NAC. They measured SUVmax, MTV, and total lesion glycolysis, and concluded that volumetric measurements of the tumor were better for predicting One prospective study with an analysis of 142 breast cancer patients found that the sensitivity, specificity, and PPV of PET/CT were significantly higher than those of MRI in the response evaluation of NAC (21) . However, we found that there were no significant differences in the sensitivity, specificity, accuracy, PPV, and NPV between PET/CT and MRI, although MRI had higher specificity (62.5% versus 25%), accuracy (75.7% versus 63.6%), and PPV (71.4% versus 58.6%), but lower sensitivity (88.2% versus 100%) and NPV (83.3% versus 100%) than that of PET/CT. Additionally, the specificity (25%) for predicting pathological responses using SULpeak in PET/CT was much lower than reported in other studies (18, 20, 32, 33) . This difference between the previous study and our study may have been due to the effects of the different timing of the follow-up PET/CT scan (after NAC completion vs. during NAC), cutoff values of SUV decline (30% versus 25-50%), and pathological criteria for a pathological response (>50% versus >25% of tumor necrosis/fibrosis or disappearance of the tumor on pathology).
The working group in RECIST 1.1 (9) did not recommend volumetric assessment of tumors in routine clinical practice because of insufficient standardization and lack of widespread availability. However, some clinical studies performed in breast cancer patients have shown that volumetric analysis in MRI is useful for the prediction of NAC responses (10, 11, 12, 34) . Partridge et al. (12) reported that MRI tumor volume before NAC and the change after NAC were significant independent predictors for recurrence-free survival. An et al. (34) found good agreement between MRI tumor volume measurements and pathological assessments for predicting NAC responses. These results are consistent with our findings that tumor volume measurements by MRI were capable of predicting NAC response in breast cancer patients.
In the present study, we used SULpeak as a semiquantitative parameter for response evaluation, as suggested in the PERCIST 1.0 recommendations. SUL value is more consistent from patient to patient than SUV for total body mass. Moreover, we did not find a statistical difference between SUVmax, SUVpeak, SULmax, and SULpeak. Inter-observer variability associated with the manual delineation performed by the two nuclear medicine physicians was significantly reduced by the use of automatic segmentation.
Theoretically, the spatial resolution is best at the center and deteriorates toward the periphery of the scanner. Therefore, the spatial resolution in a breast cancer in the more peripheral portion was worse than that in the proximal portion. However, in our study, this factor did not greatly affect the spatial resolution because the patients enrolled in our study were not obese. For a very small-sized primary breast cancer, or residual cancer after chemotherapy, the sensitivity is lower and the quantitative analysis is less reliable because of the partial volume effect. Therefore, dedicated breast PET devices might have value for small breast cancer.
The present study had several limitations. We combined the SULpeak and MTV measurements acquired from two different types of PET/CT scanner. Additionally, there is controversy in measuring MTV because no definite threshold for MTV measurement has been established, although a few studies have used an absolute value of threshold SUV or 50% of SUVmax for segmentation of the target lesion (35) (36) (37) . For MRI measurements, different scanners (1.5 T and 3 T) were used, resulting in differing spatial resolution. In addition to these limitations, the retrospective nature of the study design, the relatively small number of patients, and inhomogeneous chemotherapy regimens must be taken into account. Finally, the timing of PET/CT scanning is considered to be a serious limitation because of its limited impact on the change in treatment during chemotherapy. A further study is planned to assess the clinical impact on the treatment change according to the NAC response judged by PET/CT and MRI, with a greater number of patients and follow-up data.
In conclusion, PET/CT showed lower specificity and accuracy than MRI in evaluating response to NAC. However, there was no statistically significant difference between these parameters. SULpeak, MTV, 1D, TV after NAC, and the reduction rates of these parameters predicted pathological tumor responses. In particular, volume parameters of both PET/CT and MR may have predictive value in distinguishing pathological responders and non-responders. The use of PET/CT or MR might lead to a better decision regarding the extent of surgery (mastectomy or breast conserving surgery) in a patient who appears to be responding to NAC. In a patient who does not respond to NAC, it could lead to more aggressive treatment instead of ineffective NAC.
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